source
- Novartis CEO says shareholders remain supportive despite recent trial setbacksNovartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
- White House pulls nomination for FDA nominee OvertonThe sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.BioPharma Dive · 23h ago↗ source
- Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type C